Regavirumab

Regavirumab is a monoclonal antibody designed for the treatment of cancer. It is a type of biological therapy that targets specific proteins on cancer cells to inhibit their growth and spread.

Mechanism of Action[edit | edit source]

Regavirumab works by binding to the vascular endothelial growth factor receptor 2 (VEGFR2), a protein found on the surface of cancer cells. VEGFR2 plays a crucial role in the growth of new blood vessels, a process known as angiogenesis. By blocking VEGFR2, Regavirumab can inhibit angiogenesis, thereby starving the cancer cells of the nutrients they need to grow and multiply.

Clinical Trials[edit | edit source]

Regavirumab has been tested in several clinical trials for various types of cancer, including colorectal cancer, gastric cancer, and lung cancer. The results of these trials have shown that Regavirumab can significantly improve progression-free survival and overall survival in patients with these types of cancer.

Side Effects[edit | edit source]

Like all chemotherapy drugs, Regavirumab can cause side effects. These can include fatigue, nausea, vomiting, diarrhea, and hypertension. In rare cases, Regavirumab can also cause more serious side effects, such as bleeding, perforation of the gut, and heart failure.

Future Research[edit | edit source]

Future research on Regavirumab will likely focus on identifying which patients are most likely to benefit from this drug, as well as developing strategies to manage its side effects. In addition, researchers are also investigating the potential of combining Regavirumab with other cancer treatments to enhance its effectiveness.